ZC3H18

ZC3H18 is a multi-domain nuclear zinc finger protein that operates at the interface of RNA production and destruction, coordinating both nuclear export of capped transcripts and their exosome-mediated decay (PMID:29298432). Through a dedicated cap-binding complex (CBC)-interacting domain it associates with the CBC, while a separate region engages the nuclear exosome targeting (NEXT) complex and a phosphorylation-dependent region binds core histones; these domains are differentially required for ZC3H18's effects on transcription of subsets of protein-coding genes (PMID:29298432). On the export arm, ZC3H18 directly binds RNA—including the SEP1 sub-element of the hepatitis B virus PRE—and recruits the TREX export machinery to capped transcripts, supporting efficient nuclear export of intronless, polyA, and general polyA RNAs (PMID:24782531). On the decay arm, ZC3H18 promotes NEXT/exosome turnover of short, capped, unadenylated transcripts via ARS2, and through an acidic-rich short linear motif competes with the PAXT component ZFC3H1 for a shared ARS2 epitope, antagonizing PAXT and thereby balancing the two decay pathways (PMID:37889751). Independently of its RNA roles, ZC3H18 acts as a DNA-binding transcriptional activator at the BRCA1 promoter, binding an E2F site and recruiting E2F4 to drive BRCA1 expression; its depletion induces BRCA1 promoter methylation, impairs homologous recombination, and sensitizes ovarian cancer cells to crosslinkers and PARP inhibitors (PMID:31604914). ZC3H18 protein stability is enhanced by USP39-mediated deubiquitination, which sustains BRCA1 expression and contributes to carboplatin resistance (PMID:42205906), and its nuclear surveillance function normally suppresses endogenous retroviral RNA, with recurrent truncating mutations acting as dominant negatives that stabilize ERV transcripts and promote oncogenesis (PMID:39868094).

1. 2014 High

   Established ZC3H18 as a direct RNA-binding adaptor that recruits the TREX export machinery to capped mRNAs, defining its role in nuclear RNA export.

   Evidence Affinity purification of SEP1-RNP with mass spectrometry, RNA binding assays, co-IP with TREX components, and siRNA knockdown with nuclear export readouts

   PMID:24782531

   Open questions at the time

   • Did not resolve which TREX subunit ZC3H18 contacts directly
   • Generality of export defect across endogenous transcript classes not fully mapped
2. 2018 High

   Resolved the modular architecture of ZC3H18, showing distinct domains that bridge the CBC, the NEXT exosome-targeting complex, and histones, placing it at the production/destruction interface.

   Evidence Reciprocal co-IP/affinity purification interaction screening, domain mutagenesis, genome-wide transcriptional analyses in human cells

   PMID:29298432

   Open questions at the time

   • Mechanism by which histone association influences transcription not defined
   • How export versus decay outcomes are selected at individual loci unclear
3. 2019 High

   Revealed an unexpected chromatin-associated function: ZC3H18 binds the BRCA1 promoter as a DNA-binding protein and recruits E2F4 to activate BRCA1, linking it to homologous recombination competence.

   Evidence ChIP for ZC3H18 and E2F4 promoter occupancy, siRNA knockdown with BRCA1 readout, methylation-specific PCR, HR assays, and drug sensitivity assays in ovarian cancer cells

   PMID:31604914

   Open questions at the time

   • DNA sequence specificity and direct versus indirect promoter binding not structurally defined
   • Relationship between RNA-handling and DNA-binding functions unresolved
4. 2023 High

   Defined the molecular basis of ZC3H18's dual control of nuclear decay, showing it both activates NEXT and competitively antagonizes PAXT through a shared ARS2 binding motif.

   Evidence Mutational analysis of ZFC3H1, co-IP mapping of ZC3H18/ZFC3H1 competition for ARS2, and RNA decay assays distinguishing NEXT and PAXT substrates

   PMID:37889751

   Open questions at the time

   • Structural detail of the competing short linear motifs on ARS2 not determined
   • Physiological loci where this balance matters not comprehensively cataloged
5. 2025 Medium

   Connected ZC3H18 nuclear surveillance to tumor suppression, showing recurrent truncating mutants act as dominant negatives that stabilize rather than degrade ERV RNA and accelerate melanoma.

   Evidence Zebrafish melanoma model and engineered human melanoma cells expressing Z18trunc, RNA binding assays, and CCLE mutant data (preprint)

   PMID:39868094

   Open questions at the time

   • Single preprint lab study not yet peer-reviewed
   • Mechanism by which truncation converts decay targeting into stabilization undefined
6. 2026 Medium

   Identified a post-translational regulator of ZC3H18, showing USP39-mediated deubiquitination stabilizes the protein to sustain BRCA1 expression and drive chemoresistance.

   Evidence Co-IP of USP39–ZC3H18, western blotting for stability upon USP39 manipulation, methylation-specific PCR, Seahorse mitochondrial assays, and ZC3H18 rescue experiments

   PMID:42205906

   Open questions at the time

   • Single lab study without independent replication
   • Ubiquitin ligase opposing USP39 not identified
   • Direct link between ZC3H18 stability and mitochondrial biogenesis not mechanistically dissected

• How ZC3H18 partitions a given capped transcript between TREX-mediated export and NEXT/exosome decay, and how its chromatin/DNA-binding role is coordinated with its RNA-handling functions, remain unresolved.
• No structural model integrating CBC, NEXT, TREX, and ARS2 interactions
• Signals governing export-versus-decay choice unknown
• Mechanistic link between DNA-binding transcriptional role and RNA surveillance role unestablished